Adam Stern Reports 20,000 Restricted Share Award at DarioHealth (DRIO)
Rhea-AI Filing Summary
Adam K. Stern, a director of DarioHealth Corp. (DRIO), reported a restricted stock award of 20,000 shares granted on 09/11/2025 at a $0 price. The award is scheduled to vest on the last day of the second-year anniversary after the grant date. Following the reported transaction and reflecting a 20-for-1 reverse stock split effected on August 28, 2025, the filing shows 29,717 shares beneficially owned directly and 6,146 shares beneficially owned indirectly through AKS Family Partners L.P. The filing also discloses indirect beneficial ownership of 123,763 Series-C preferred shares. The form is signed by Mr. Stern on 09/15/2025.
Positive
- Restricted award disclosed with clear vesting schedule, indicating alignment of director incentives with long-term shareholder value
- Timely and complete Form 4 filing signed by the reporting person on 09/15/2025
- Disclosure includes impact of 20-for-1 reverse split, clarifying post-split share counts
Negative
- None.
Insights
TL;DR: Routine insider grant with multi-year vesting aligns director incentives but does not signal immediate change in control or strategy.
The reported grant of 20,000 restricted common shares at $0 with a vesting date two years after grant is a common form of long-term compensation for directors intended to align interests with shareholders. The filing discloses both direct and indirect holdings and notes the recent 20-for-1 reverse split, which explains the presented share counts. There is no indication in the filing of accelerated vesting, option exercise, or disposal activity that would materially change governance dynamics. Disclosure appears timely and complete for a single reporting person Form 4.
TL;DR: Non-cash restricted award increases reported insider ownership but is a routine disclosure without immediate market impact.
The 20,000-share restricted award recorded at a $0 price increases Mr. Stern's direct reported holdings to 29,717 shares after the companys 20-for-1 reverse split. The filing also confirms indirect positions: 6,146 common shares and 123,763 Series-C preferred shares held via AKS Family Partners L.P. Because the grant vests over two years, the award represents a retention incentive rather than immediate liquidity or sale. There is no derivative activity reported and no sales or transfers disclosed that would signal near-term insider divestiture.